Sunday
2:00 pm - 9:00 pm
Arrival and Check-in
6:00 pm - 7:00 pm
Dinner
7:30 pm - 7:40 pm
Introductory Comments by GRC Site Staff / Welcome from the GRC Chair
7:40 pm - 9:30 pm
Keynote Session: From B Cell Activation to Engineered Antibodies
7:40 pm - 7:50 pm
Opening Remarks
7:50 pm - 8:30 pm
"Informing Vaccine Design by Defining the Rules of Antibody Responses"
8:30 pm - 8:40 pm
Discussion
8:40 pm - 9:20 pm
"In Situ Biosynthesis of Therapeutic Antibodies and Other Bio-therapeutics: the Treatment from within."
9:20 pm - 9:30 pm
Discussion
Monday
7:30 am - 8:30 am
Breakfast
9:00 am - 12:30 pm
Antibodies Against Infectious Disease Agents
This session will elaborate on the diversity of antibodies against viruses, such as HIV, influenza and SARS-Cov-2, from B cells to antibody design and implications for vaccines.
9:00 am - 9:10 am
Introduction by Discussion Leader
9:10 am - 9:35 am
"Insights into B Cell Responses and Antibody Immune Correlates of Natural Dengue and Zika Virus Infections"
9:35 am - 9:45 am
Discussion
9:45 am - 10:10 am
"The Known and Unknown of Antibodies Against Influenza Hemagglutinin"
10:10 am - 10:20 am
Discussion
10:20 am - 10:50 am
Group Photo / Coffee Break
10:50 am - 11:15 am
"Engineering-Based Approaches to Improve HIV bnAb Function"
11:15 am - 11:25 am
Discussion
11:25 am - 11:50 am
"Human Antibodies from Puumala Virus-Convalescent Donors Provide Broad Protection Against Hantaviruses"
11:50 am - 12:00 pm
Discussion
12:00 pm - 12:10 pm
"Keeping Pace with a Pandemic: An Integrated Technology Stack to Discover and Develop Antibody Treatments"
12:10 pm - 12:15 pm
Discussion
12:15 pm - 12:25 pm
"Protective Effects of Combining Monoclonal Antibodies and Vaccines Against the Plasmodium Falciparum Circumsporozoite Protein"
12:25 pm - 12:30 pm
Discussion
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
3:00 pm - 4:00 pm
The GRC Power Hourâ„¢
The GRC Power Hourâ„¢ is designed to address challenges women face in science and issues of diversity and inclusion. The program supports the professional growth of all members of our communities by providing an open forum for discussion and mentoring.
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Antibody Interactions with Fc Receptors
This session looks at the recent developments in analysis and manipulation of effector functions of human effector leukocytes, particularly through classical and non-classical Fc receptors. The session also deals with the interplay between effector mechanisms and exogenous factors that influence effector function outcomes in vivo.
7:30 pm - 7:55 pm
"Dissecting the Mechanisms of ITAM Activation"
7:55 pm - 8:05 pm
Discussion
8:05 pm - 8:30 pm
"Novel Humanized Mouse Models for Antibody Effector Function and Disease"
8:30 pm - 8:40 pm
Discussion
8:40 pm - 9:05 pm
"Targeting FcRn for Therapy"
9:05 pm - 9:15 pm
Discussion
9:15 pm - 9:25 pm
"FcRn-IgG Interactions Control Innate Immune Sensing"
9:25 pm - 9:30 pm
Discussion
Tuesday
7:30 am - 8:30 am
Breakfast
9:00 am - 12:30 pm
Antibody Structure in Relation to Function
This session focuses on new insights into how natural antibody structure influences function and considers how antibodies can be manipulated to direct new or preferred functions. This session will include novel antibody-like molecules and new bispecific antibody technologies.
9:00 am - 9:10 am
Introduction by Discussion Leader
9:10 am - 9:35 am
"Neutralizing Antibodies against Pandemic Viruses"
9:35 am - 9:45 am
Discussion
9:45 am - 10:10 am
"Structural Correlates of Antibody Affinity Maturation in the Human Immune Response to Influenza Virus"
10:10 am - 10:20 am
Discussion
10:20 am - 10:50 am
Coffee Break
10:50 am - 11:15 am
"Antibodies Against SARS-CoV-2: A Global Consortium"
11:15 am - 11:25 am
Discussion
11:25 am - 11:50 am
"Engineering Antibodies to Disrupt Stable Receptor Complexes and Disarm Allergic Effector Cells"
11:50 am - 12:00 pm
Discussion
12:00 pm - 12:10 pm
"A Mechanistic Model of Antigen- and IgG Subclass Dependent Antibody Oligomerization and Complement Binding"
12:10 pm - 12:15 pm
Discussion
12:15 pm - 12:25 pm
"A Trastuzumab-like Monoclonal Antibody Engineered With IgE Fc Regions Can Exert Potent Anti-Tumour Functions"
12:25 pm - 12:30 pm
Discussion
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Antibody Engineering
This session will focus on how antibodies can be manipulated to direct new or preferred functions. This session will include novel antibody-like molecules and new bispecific antibody technologies.
7:30 pm - 7:55 pm
"Intratumoral Administration and Anchoring of Agonistic Antibodies Drives Significant Improvement in Therapeutic Index"
7:55 pm - 8:05 pm
Discussion
8:05 pm - 8:30 pm
"Fine-tuned Engagement of FcRn guides Design of Biologics with Favorable Properties"
8:30 pm - 8:40 pm
Discussion
8:40 pm - 9:05 pm
"Probing the Molecular Basis of High Viscosity of Monospecific and Bispecific IgG Antibodies"
9:05 pm - 9:15 pm
Discussion
9:15 pm - 9:25 pm
"TNB-486: An Anti-CD19xCD3 T-Cell Engager With a Better Therapeutic Window"
9:25 pm - 9:30 pm
Discussion
Wednesday
7:30 am - 8:30 am
Breakfast
9:00 am - 12:30 pm
Agonistic and Antagonistic Antibodies for Cancer Immunotherapy
This session will focus on how activation of immune cells can lead to cancer therapy, either by targeting inhibitory receptors on T cells, or engineering for agonistic antibodies, or targeting the tumor microenvironment.
9:00 am - 9:10 am
Opening Remarks
9:10 am - 9:35 am
"Discovery of Novel Antibody Interfaces to Guide Biotherapeutic Engineering"
9:35 am - 9:45 am
Discussion
9:45 am - 10:10 am
"Fc Receptors and Immunomodulatory Antibodies"
10:10 am - 10:20 am
Discussion
10:20 am - 10:50 am
Coffee Break
10:50 am - 11:15 am
"Implications of Tumor pH - Biology and Conditional Activation"
11:15 am - 11:25 am
Discussion
11:25 am - 11:50 am
"Manipulating the Innate-Adaptive Immune Interface with CD27 Stimulation for Effective Anti-Cancer Therapy"
11:50 am - 12:00 pm
Discussion
12:00 pm - 12:10 pm
"Discovery and Pre-Clinical Development of an Anti-EphA2, Tumor-Targeting Therapeutic from a Cancer Patient Antibody"
12:10 pm - 12:15 pm
Discussion
12:15 pm - 12:25 pm
"FS222 is a Tetravalent Bispecific Antibody Designed for Optimal T Cell Activation Without Toxicity"
12:25 pm - 12:30 pm
Discussion
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Dissecting B Cell Responses
This session examines the generation of antibody responses at the B cell level. The heterogeneity and function of different B cell subsets will be discussed.
7:30 pm - 7:55 pm
"Plasma IgG Proteomics for the Investigation of Experimental Vaccines and Emerging Infectious Diseases"
7:55 pm - 8:05 pm
Discussion
8:05 pm - 8:30 pm
"Analysis of Rare Antigen-Specific Naïve B Cells"
8:30 pm - 8:40 pm
Discussion
8:40 pm - 9:05 pm
"B Cell Receptor Engagement: Toggling Between Tolerance and Immunity"
9:05 pm - 9:15 pm
Discussion
9:15 pm - 9:25 pm
"Gene-Endowed Antibody Targeting of Influenza Virus"
9:25 pm - 9:30 pm
Discussion
Thursday
7:30 am - 8:30 am
Breakfast
8:30 am - 9:00 am
Business Meeting
Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair
9:00 am - 12:30 pm
Cancer Immunotherapy Employing Innate Immune Cells
To date, immunotherapy has mainly focused on T cells, B cells and dendritic cells. This session focuses on the potential for employing innate immune cells or myeloid cells as anti-cancer effector cells.
9:00 am - 9:10 am
Opening Remarks
9:10 am - 9:35 am
"Targeting the Inhibitory Receptor CD161 in T cells"
9:35 am - 9:45 am
Discussion
9:45 am - 10:10 am
"Harnessing Innate Immune Cells with Multispecific Antibodies"
10:10 am - 10:20 am
Discussion
10:20 am - 10:50 am
Coffee Break
10:50 am - 11:15 am
"IgE Immunotherapy: Targeting Cancer by Re-Educating Macrophages"
11:15 am - 11:25 am
Discussion
11:25 am - 11:50 am
"Myeloid Checkpoint Blockade to Improve PMN Recruitment of Tumor Immunotherapy"
11:50 am - 12:00 pm
Discussion
12:00 pm - 12:10 pm
"Antibody-Lectin Bispecifics for Glyco-Immune Checkpoint Blockade"
12:10 pm - 12:15 pm
Discussion
12:15 pm - 12:25 pm
"IgA3.0 Dinutuximab as Treatment for High-Risk Neuroblastoma"
12:25 pm - 12:30 pm
Discussion
12:30 pm - 1:30 pm
Lunch
1:30 pm - 4:00 pm
Free Time
4:00 pm - 6:00 pm
Poster Session
6:00 pm - 7:00 pm
Dinner
7:30 pm - 9:30 pm
Pre-Clinical Antibody Evaluation
This session will provide new perspectives on the development and evaluation of therapeutic antibodies.
7:30 pm - 8:00 pm
"Mobilizing the Immune System with Bispecific Antibodies and Potency-Reduced Cytokines"
8:00 pm - 8:10 pm
Discussion
8:10 pm - 8:35 pm
"Bispecific Antibodies and Gamma-Delta T Cell Engagers for the Treatment of Cancer"
8:35 pm - 8:45 pm
Discussion
8:45 pm - 8:55 pm
"Fc Engineered Monoclonal Antibodies for Triple Negative Breast Cancer Therapy"
8:55 pm - 9:00 pm
Discussion
9:00 pm - 9:10 pm
"Discovery Approaches for the Development of Therapeutic Multispecific Antibodies"
9:10 pm - 9:15 pm
Discussion
9:15 pm - 9:25 pm
"Hetero-Fc Pairing for Multi-Specific Antibodies"
9:25 pm - 9:30 pm
Discussion
Friday
7:30 am - 8:30 am
Breakfast
9:00 am
Departure